HomeInsightsStock Comparison

Kopran Ltd vs Rpg Life Sciences Ltd Stock Comparison

Kopran Ltd vs Rpg Life Sciences Ltd Stock Comparison

Last Updated on: Jul 19, 2025

Key Highlights

  • The Latest Trading Price of Kopran Ltd is ₹ 178.1 as of 18 Jul 15:30.
  • The P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 yearsThe P/E Ratio of RPG Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 yearsThe Market Cap of RPG Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Kopran Ltd for the Mar '25 is ₹ 175.62 crore as compare to the Dec '24 revenue of ₹ 166.41 crore. This represent the growth of 5.53% The revenue of RPG Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Kopran Ltd for the Mar '25 is ₹ 20.35 crore as compare to the Dec '24 ebitda of ₹ 20.01 crore. This represent the growth of 1.7% The ebitda of RPG Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 9.68 crore over 8 quarters. This represents a CAGR of 86.94% The net profit of RPG Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of RPG Life Sciences Ltd changed from 24.66 % on March 2020 to 18.05 % on March 2025 . This represents a CAGR of -5.07% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

About RPG Life Sciences Ltd

  • RPG Life Sciences Limited, formerly known as Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group.
  • The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited'.
  • During the year 2007-08, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007.
  • On February 13, 2008, the name of the Company was changed to RPG Life Sciences Limited. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes.

Kopran Ltd News Hub

News

Kopran to table results

Kopran will hold a meeting of the Board of Directors of the Company on 29 July 2025. Power...

Read more

19 Jul 2025 10:03

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

News

Kopran allots 36,200 equity shares under ESOP

Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotmen...

Read more

21 Jan 2025 18:36

RPG Life Sciences Ltd News Hub

News

RPG Life Sciences to conduct board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 25 July ...

Read more

19 Jul 2025 10:29

News

RPG Life Sciences schedules AGM

RPG Life Sciences announced that the 18th Annual General Meeting(AGM) of the company will ...

Read more

16 Jun 2025 15:14

News

Board of RPG Life Sciences recommends special dividend

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held...

Read more

29 Apr 2025 09:35

News

Board of RPG Life Sciences recommends final dividend

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held...

Read more

29 Apr 2025 09:35

News

RPG Life edges higher after Q4 PAT rises 64% YoY to nearly Rs 22 crore

Net sales rose by 12.7% year-over-year (YoY) to Rs 143.09 crore during the period under re...

Read more

29 Apr 2025 11:35

News

RPG Life Sciences to hold board meeting

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 28 April...

Read more

22 Apr 2025 09:39

SWOT Analysis Of RPG Life Sciences Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for RPG Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Kopran Ltd and RPG Life Sciences Ltd

Which company has a larger market capitalization, Kopran Ltd or RPG Life Sciences Ltd?

Market cap of Kopran Ltd is 859 Cr while Market cap of RPG Life Sciences Ltd is 4,149 Cr

What are the key factors driving the stock performance of Kopran Ltd and RPG Life Sciences Ltd?

The stock performance of Kopran Ltd and RPG Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and RPG Life Sciences Ltd?

As of July 19, 2025, the Kopran Ltd stock price is INR ₹178.1. On the other hand, RPG Life Sciences Ltd stock price is INR ₹2508.85.

How do dividend payouts of Kopran Ltd and RPG Life Sciences Ltd compare?

To compare the dividend payouts of Kopran Ltd and RPG Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions